Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T20:37:17.368Z.
Calculation as of: 2026-10-06T20:37:17.368Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 53f0b653117dfddf80d57e74ba570551200adc0db5709ea8e1a3c029d43ac92d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$2.70B
PS Ratio
0.80
TTM Avg
0.64
3Y Avg
1.30
5Y Avg
1.84
Market Cap
$2.66B
PS Ratio
1.02
TTM Avg
0.82
3Y Avg
0.54
5Y Avg
0.45
Market Cap
$2.60B
PS Ratio
365.60
TTM Avg
189.81
3Y Avg
133.81
5Y Avg
91.05
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $2.71B | N/A | N/A | N/A | N/A |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | 0.80 | 0.64 | 1.30 | 1.84 |
| Precigen, Inc. (PGEN)vs › | $2.69B | 31.40 | 132.61 | 101.64 | 68.12 |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 4.79 | 3.27 | 3.39 | 5.20 |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.66B | 1.02 | 0.82 | 0.54 | 0.45 |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 4.15 | 7.07 | 9.70 | 14.76 |
| Neogen Corporation (NEOG)vs › | $2.61B | 3.00 | 2.29 | 2.71 | 4.02 |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.60B | 365.60 | 189.81 | 133.81 | 91.05 |
| Beam Therapeutics Inc. (BEAM)vs › | $2.60B | 16.63 | 30.54 | 21.36 | 4962.99 |
| Privia Health Group, Inc. (PRVA)vs › | $2.56B | 1.08 | 1.41 | 1.51 | 1.99 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
